Read the Conversation
Conversation highlights:
- The UAE combines ambition with execution effectiveness, making it a unique reference market for early innovation adoption and global healthcare advancement.
- Healthcare systems are shifting focus from short-term interventions to long-term value creation through data-driven evidence generation and integrated patient care.
- Strategic public-private partnerships enable comprehensive care pathways that go beyond treatment to create sustainable healthcare solutions.
- The evolving workforce requires both technical digital skills and behavioral adaptability, with continuous learning becoming the key differentiator for talent.
- System readiness for innovation involves not just fast approvals but collaborative frameworks for health technology assessment and sustainable implementation.
- Healthcare must be viewed as an investment in human capital rather than merely a cost, requiring mindset shifts across all stakeholders.
EF: What are your key priorities and focus areas for 2026 in the UAE healthcare market?
ME: Healthcare systems are undergoing a fundamental shift toward creating long-term value rather than simply pursuing innovation. This transformation centers on three critical priorities that will define our approach in 2026 and beyond:
- First, we're addressing the growing burden of non-communicable diseases through earlier intervention and improved long-term disease management. The focus has moved beyond reactive treatment to proactive, comprehensive care strategies.
- Second, data and evidence generation have become central to informing healthcare decisions. We're moving beyond short-term horizons to leverage data that can guide sustainable healthcare system improvements and patient outcomes.
- Third, ensuring innovation is matched by system readiness represents our most complex challenge. This means not only adopting new technologies but also developing the right assessment frameworks and infrastructure to support sustainable implementation.
The opportunity lies in moving beyond episodic interventions toward integrated care across the entire patient journey. We're still in the early phases of effective data utilization, which requires enhanced collaboration across multiple entities and organizations. This isn't a challenge but rather an evolution that demands coordinated effort to maximize the potential of technological advancement.
EF: What makes the UAE strategically significant to Roche beyond its market size?
ME: The UAE represents a unique combination of ambition and execution effectiveness that sets it apart as a reference market globally. This market engages with innovation exceptionally early, supported by robust fast-tracking systems that bring treatments and technological advancements to patients quickly.
What makes the UAE truly distinctive is its willingness to adopt innovation across multiple dimensions, not just products, but also ideation and concepts that can be exported worldwide. The market serves as both an early adopter and an ambassador for innovation, supported by the right infrastructure and collaborative environment.
Our partnerships exemplify this approach, particularly our collaborations with the Department of Health of Abu Dhabi and Abu Dhabi Public Health Center. These relationships focus on innovation-driven evidence generation, comprehensive care pathway development, and solutions that extend beyond traditional treatment models.
The public-private partnership framework creates an enabling environment for healthcare-sector collaborations to flourish. This combination of early adoption capability, an ambassador role in global innovation, and an effective execution infrastructure makes the UAE an invaluable strategic market that influences healthcare development far beyond its geographic boundaries.
EF: How do you assess the current use of data in the UAE healthcare system, and what frameworks are needed to maximize patient benefits?
ME: Data has become the central foundation for transforming healthcare from reactive to predictive and personalized. Better disease understanding at both individual and population levels enables more accurate, targeted interventions that drive superior outcomes and efficient resource utilization.
The UAE has created remarkable momentum through strategic government investments in diagnostics, genomics, and data infrastructure. Initiatives like the Emirati Genome Program demonstrate how coordinated efforts lay the foundation for high-quality data generation and utilization.
Good-quality data enables evidence generation and identifies intervention opportunities across the full patient journey, from awareness and diagnostics through treatment and post-treatment care. The collaborative environment we've established enables us to use this data effectively to inform healthcare systems and implement precise interventions.
At Roche, our operational focus ensures personalized healthcare translates into real-world patient benefits. This requires not just data collection but sophisticated frameworks for analysis, interpretation, and application that can guide clinical decision-making and system-wide improvements. The infrastructure investments and collaborative partnerships position the UAE to lead in data-driven healthcare transformation.
EF: How does the UAE's approach to innovation adoption and system readiness support sustainable healthcare advancement?
ME: The UAE has created an exceptionally unique environment for the adoption of innovation that operates on multiple levels simultaneously. Following FDA or EMA approvals, the Emirates Drug Establishment and Administration accepts filings and implements fast-track processes that are unmatched globally.
Once regulatory approval occurs, open dialogue with reimbursement bodies, whether the Department of Health or Dubai Health Authority, creates transparent pathways for innovation access. Most significantly, we have an evolving health technology assessment system that examines the totality of evidence, including clinical, economic, and societal impact.
This comprehensive approach means innovation discussions extend beyond traditional clinical endpoints to encompass broader value propositions. The system's maturity allows for continuous learning and collaboration, with authorities genuinely seeking support and asking the right questions to optimize outcomes.
Over seven years, I've observed that dialogue with authorities here is uniquely collaborative. They actively seek partnership and expertise, creating a platform that supports long-term innovation and learning rather than short-term adoption. This collaborative nucleus enables sustainable innovation implementation that benefits patients, healthcare systems, and society comprehensively.
EF: What kind of talent and capabilities does Roche need to succeed in this evolving digital healthcare landscape?
ME: It’s amazing to see how technology has transformed. I often joke with my team that I am from the generation that used overhead projectors for presentations. AI-enabled healthcare represents a dramatic advancement that requires both foundational excellence and cutting-edge capabilities. Sustaining innovation, improving healthcare delivery, and enabling effective collaboration demands a specific combination of technical and leadership skills.
The UAE provides an exceptional talent environment where international expertise meets local insights, supported by a robust education system that develops local talent. This diversity creates a cosmopolitan talent pool with differentiated perspectives across multiple categories and backgrounds.
Technical skills must be built on core marketing and medical foundations while incorporating digital savviness, an understanding of data quality, and data utilization capabilities. Digital health expertise has become essential, not optional.
Behaviorally, we need system-level thinking, adaptability, agility, and cross-disciplinary collaboration capabilities. The ability to connect dots across complex healthcare ecosystems has become crucial for success.
At Roche, we invest heavily in continuous learning for both technical skills and leadership development. However, the single most important quality I seek is a candidate's ability to learn and implement. In this competitive, diverse market, the willingness and capacity to continuously adapt and grow determine long-term success more than any specific starting point.
EF: Reflecting on your decade at Roche, what moments stand out as your proudest achievements?
ME: My proudest moments aren't singular events but rather the continuous instances where I've successfully delivered on my commitment to develop effective teams and leaders. I feel obligated to work with my leadership team to create environments where people can drive meaningful change.
The moments that give me the greatest satisfaction are when we bring innovation fueled by science to patients through collaborative efforts and system readiness initiatives, but accomplished through empowered people. When team members successfully drive innovation, collaboration, and system readiness, I know I've delivered on my fundamental purpose as a leader.
After seven years as General Manager, I can confidently say we've successfully delivered on this commitment. The real achievement isn't any single milestone but the sustained development of people who continue to push boundaries and create positive change in healthcare.
These are the moments that create genuine excitement and pride, when people become the driving force behind innovation and collaboration. That's when leadership truly succeeds, and that's what continues to motivate me after 26 years in this industry.
EF: What final message would you like to share about the future of healthcare?
ME: As innovation accelerates and artificial intelligence transforms healthcare capabilities, there's a pressing need for a fundamental mindset shift across our entire healthcare ecosystem. Every stakeholder, from healthcare professionals and system administrators to the broader public, must recognize that healthcare represents an investment in human capital, not merely a cost center.
This perspective shift becomes critical as we deploy increasingly sophisticated innovations. The level of awareness and understanding required to assess, deploy, and maximize these advancements effectively demands that we view healthcare through an investment lens.
The transformation starts with individual recognition within healthcare systems, extends to surrounding stakeholders, and ultimately reaches the wider community. Only when we collectively understand healthcare as an investment in human potential can we properly accommodate and leverage the remarkable advancements emerging in our field.
This mindset change isn't just philosophical; it's practical and necessary for sustainable healthcare evolution. When we invest in healthcare, we invest in human capital, societal productivity, and long-term prosperity. This understanding will determine how successfully we navigate the innovation-rich future ahead of us.
